The probability of NCI receiving a boost in funds over the next two years is slim, NCI Director Monica Bertagnolli said at the joint meeting of the National Cancer Advisory Board and Board of Scientific Advisors June 14.
NCI has released the language of the much-discussed National Cancer Plan, an eight-goal blueprint that spans the spectrum of cancer care—prevention, treatment, and survivorship—to correspond with President Joe Biden’s vision of cutting cancer mortality by half in 25 years.
NCI is on the cusp of releasing designs for its National Cancer Plan, an initiative that would guide the institute’s mission and portfolio for years to come and engage everyone in oncology to “end cancer as we know it,” said NCI Director Monica Bertagnolli.
NCI is increasing the R01 payline to the 12th percentile in fiscal year 2023, up from the 11th percentile in FY22—bringing the institute’s payline to a level not seen since 2010.
It’s time to supercharge NCI’s role in redefining clinical trials and in strengthening the cancer research enterprise, NCI Director Monica Bertagnolli said Nov. 9 in her first director’s report.
In her first public speech as NCI director, Monica Bertagnolli said that under her stewardship NCI would modernize clinical trials and double patient accrual.
“Yesterday, I went to sleep as acting NCI director, and this morning, as I woke up, I have a new boss, Monica Bertagnolli,” Douglas R. Lowy said in the morning of Oct. 3, addressing a well-caffeinated meeting of the Association of American Cancer Institutes.
Drawing on Charles Dickens, NCI Acting Director Douglas Lowy has a teaching moment for oncology: we live in the best of times as well as the worst of times, because only fragments of human society—both in the United States and in low- and middle-income countries—fully benefit from modern cancer care.
As NCI prepares for a transition of leadership, Acting Director Douglas Lowy is setting out an agenda focused on multi-cancer detection tests, undruggable targets, cell therapy, and on eliminating disparities caused by persistent poverty.
In the next phase of the Cancer Moonshot, NCI will focus on investing in the development and testing of new modalities, including multi-cancer early detection assays, and fostering diversity in oncology, NCI Acting Director Douglas R. Lowy said at a joint meeting of the Board Of Scientific Advisors and the National Cancer Advisory Board.
